Enovis (ENOV) Expected to Announce Earnings on Thursday

Enovis (NYSE:ENOV) will likely be releasing its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect Enovis to post earnings of $0.81 per share and revenue of $584.30 million for the quarter. Investors can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Thursday, February 26, 2026 at 8:30 AM ET.

Enovis Stock Performance

Shares of ENOV stock opened at $22.08 on Thursday. The firm has a 50 day moving average of $24.77 and a 200-day moving average of $28.39. The company has a market cap of $1.26 billion, a price-to-earnings ratio of -0.93 and a beta of 1.52. The company has a quick ratio of 1.16, a current ratio of 2.22 and a debt-to-equity ratio of 0.66. Enovis has a 52 week low of $21.00 and a 52 week high of $44.76.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on the stock. BTIG Research began coverage on shares of Enovis in a research note on Tuesday, January 6th. They issued a “buy” rating and a $41.00 price target for the company. Wells Fargo & Company raised their target price on Enovis from $41.00 to $42.00 and gave the company an “overweight” rating in a research note on Friday, November 7th. Evercore reaffirmed an “outperform” rating on shares of Enovis in a research note on Monday, January 12th. UBS Group reiterated a “buy” rating and issued a $50.00 price target on shares of Enovis in a report on Monday, January 5th. Finally, Canaccord Genuity Group decreased their price objective on Enovis from $58.00 to $50.00 and set a “buy” rating for the company in a report on Wednesday, December 17th. Seven research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $46.71.

Insider Transactions at Enovis

In other Enovis news, EVP Daniel A. Pryor sold 999 shares of the business’s stock in a transaction that occurred on Tuesday, December 9th. The stock was sold at an average price of $27.20, for a total transaction of $27,172.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider John Kleckner acquired 2,468 shares of the stock in a transaction dated Tuesday, November 25th. The stock was bought at an average cost of $30.32 per share, with a total value of $74,829.76. Following the completion of the purchase, the insider owned 12,302 shares of the company’s stock, valued at approximately $372,996.64. The trade was a 25.10% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. 2.70% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Enovis

Several large investors have recently bought and sold shares of the stock. Arax Advisory Partners bought a new stake in shares of Enovis in the 4th quarter worth $29,000. EverSource Wealth Advisors LLC grew its position in Enovis by 125.4% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company’s stock worth $40,000 after purchasing an additional 707 shares in the last quarter. Danske Bank A S bought a new stake in Enovis in the 3rd quarter worth about $64,000. iSAM Funds UK Ltd purchased a new stake in Enovis in the 3rd quarter valued at about $80,000. Finally, Brown Brothers Harriman & Co. bought a new position in shares of Enovis during the 3rd quarter worth approximately $90,000. 98.45% of the stock is currently owned by institutional investors.

About Enovis

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.